bluebird bio (BLUE) Expected to Announce Earnings on Monday

bluebird bio (NASDAQ:BLUE) is expected to announce its earnings results on Monday, March 24th. Analysts expect the company to announce earnings of ($6.30) per share and revenue of $27.07 million for the quarter.

bluebird bio Stock Down 1.5 %

Shares of NASDAQ BLUE opened at $3.90 on Friday. The company has a 50 day simple moving average of $5.97 and a 200-day simple moving average of $8.03. The company has a market capitalization of $37.92 million, a P/E ratio of -0.10 and a beta of 0.76. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.51 and a quick ratio of 0.33. bluebird bio has a 1 year low of $3.56 and a 1 year high of $29.00.

Analysts Set New Price Targets

BLUE has been the subject of several research reports. Wells Fargo & Company dropped their target price on shares of bluebird bio from $40.00 to $5.00 and set an “equal weight” rating for the company in a report on Monday, February 24th. JPMorgan Chase & Co. upgraded shares of bluebird bio from an “underweight” rating to a “neutral” rating in a report on Monday, February 24th. StockNews.com initiated coverage on shares of bluebird bio in a report on Thursday. They issued a “sell” rating for the company. Barclays lifted their target price on shares of bluebird bio from $2.00 to $40.00 and gave the company an “overweight” rating in a report on Tuesday, December 31st. Finally, Baird R W downgraded shares of bluebird bio from a “strong-buy” rating to a “hold” rating in a report on Friday, February 21st. One research analyst has rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $51.00.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.